Vincent Planche
banner
vincentplanche.bsky.social
Vincent Planche
@vincentplanche.bsky.social
Professor of Neurology, Bordeaux University - Head of Memory Clinic, Bordeaux University Hospital
By combining brain charts for the human lifespan and 1,341 MRIs from subjects with a FTLD mutation, we described the age of onset of the first anatomical abnormalities, the duration of the presymptomatic phase, the chronological staging of atrophy progression, and the severity of regional atrophy.
May 27, 2025 at 8:18 PM
This letter, co-written with @suzanneeschindler.bsky.social , David Knopman, Giovanni Frisons, Douglas Galasko, Joshua Grill, Lon S. Schneider, Jason Karlawish and @nvillain-alz.bsky.social , is a response to the previously published Perspective Article by Paul Aisen and colleagues.
April 17, 2025 at 7:00 PM
Many thanks to Erwan Bezard, who co-lead this work, and to all the co-authors: Valentine Kulifaj, Marie-Laure Arotçarena, Qin Li, Taxiarchis Katsinelos, William A. McEwan, Maria Xilouri, and @benjamindehay.bsky.social DEHAY!
April 13, 2025 at 8:17 AM
Taken together, our findings align with the growing body of literature indicating that co-pathologies can significantly influence the severity and progression of neurodegenerative diseases.
April 13, 2025 at 8:16 AM
We found that the distant injection of LB or AD-tau induced nigral TH neuronal loss of 26.5% and 38.4%, respectively. Notably, the co-injection of these aggregates into distinct but anatomically connected regions to the mesencephalon resulted in an additive effect with 53.5% neuronal loss
April 13, 2025 at 8:15 AM
we reported for the first time the cooperation between LB and tau pathologies in this experimental context. We found that the injection of AD-tau could induce distant pSyn, whereas we did not observe the reverse phenomenon; the injection of LB did not induce distant AT8-positive tau phosphorylation
April 13, 2025 at 8:14 AM
We used in this study our innovative approach consisting of injecting patient-derived proteopathic aggregates into macaques’ brains, to address the issue of a putative contribution of tau versus α-synuclein pathologies to the survival of dopaminergic mesencephalic neurons.
April 13, 2025 at 8:12 AM
Reposted by Vincent Planche
Lien vers le communiqué de presse "vers la définition d’un cadre d’utilisation des biomarqueurs sanguins
de la maladie d’Alzheimer en pratique clinique" : www.chu-bordeaux.fr/Espace-m%C3%...
www.chu-bordeaux.fr
April 7, 2025 at 12:06 PM
The main message of this study is that neuropsychological examination remains fundamental for interpreting the results of AD plasma biomarkers (ptau217)
April 4, 2025 at 11:16 AM